# DP-R213 Pharmacokinetics Study

> **NCT02762643** · PHASE1 · COMPLETED · sponsor: **Alvogen Korea** · enrollment: 61 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** DP-R213
- **DRUG:** Raloxifene
- **DRUG:** Cholecaliferol

## Key facts

- **NCT ID:** NCT02762643
- **Lead sponsor:** Alvogen Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2016-07
- **Final completion:** 2016-08
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2016-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02762643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02762643, "DP-R213 Pharmacokinetics Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02762643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*